Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online August 14, 2008
Stem Cells Vol. 26 No. 11 November 2008, pp. 2865 -2874
doi:10.1634/stemcells.2007-1028; www.StemCells.com
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
2007-1028v1
26/11/2865    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weiss, M. L.
Right arrow Articles by McIntosh, K. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiss, M. L.
Right arrow Articles by McIntosh, K. R.

TISSUE-SPECIFIC STEM CELLS

Immune Properties of Human Umbilical Cord Wharton's Jelly-Derived Cells

Mark L. Weissa, Cameron Andersona, Satish Medicettyc, Kiran B. Seshareddya, Rita J. Weissa, Irene VanderWerffa, Deryl Troyera, Kevin R. McIntoshb

aDepartment of Anatomy and Physiology, Kansas State University, Manhattan, Kansas, USA;
bCognate BioServices, Baltimore, Maryland, USA;
cNeoStem, Inc., Boston, Massachusetts, USA

Key Words. Adherent cells • Immunogenicity • Immunosuppression • In vitro culture • Stromal cell

Correspondence: Correspondence: Mark L. Weiss, Ph.D., Department of Anatomy and Physiology, Kansas State University, Manhattan, Kansas 66506, USA. Telephone: 785-532-4520; Fax: 785-532-4557; e-mail: weiss{at}vet.ksu.edu

Received on December 10, 2007; accepted for publication on July 28, 2008.

First published online in STEM CELLS EXPRESS  August 14, 2008.


Cells isolated from Wharton's jelly, referred to as umbilical cord matrix stromal (UCMS) cells, adhere to a tissue-culture plastic substrate, express mesenchymal stromal cell (MSC) surface markers, self-renew, and are multipotent (differentiate into bone, fat, cartilage, etc.) in vitro. These properties support the notion that UCMS cells are a member of the MSC family. Here, the immune properties of UCMS cells are characterized in vitro. The overall hypothesis is that UCMS cells possess immune properties that would be permissive to allogeneic transplantation. For example, UCMS cells will suppress of the proliferation of "stimulated" lymphocytes (immune suppression) and have reduced immunogenicity (e.g., would be poor stimulators of allogeneic lymphocyte proliferation). Hypothesis testing was as follows: first, the effect on proliferation of coculture of mitotically inactivated human UCMS cells with concanavalin-A-stimulated rat splenocytes was assessed in three different assays. Second, the effect of human UCMS cells on one-way and two-way mixed lymphocyte reaction (MLR) assays was determined. Third, the expression of human leukocyte antigen (HLA)-G was examined in human UCMS cells using reverse transcription-polymerase chain reaction, since HLA-G expression conveys immune regulatory properties at the maternal-fetal interface. Fourth, the expression of CD40, CD80, and CD86 was determined by flow cytometry. Fifth, the cytokine expression of UCMS cells was evaluated by focused gene array. The results indicate that human UCMS cells inhibit splenocyte proliferation response to concanavalin A stimulation, that they do not stimulate T-cell proliferation in a one-way MLR, and that they inhibit the proliferation of stimulated T cells in a two-way MLR. Human UCMS cells do not inhibit nonstimulated splenocyte proliferation, suggesting specificity of the response. UCMS cells express mRNA for pan-HLA-G. UCMS cells do not express the costimulatory surface antigens CD40, CD80, and CD86. UCMS cells express vascular endothelial growth factor and interleukin-6, molecules previously implicated in the immune modulation observed in MSCs. In addition, the array data indicate that UCMS cells make a cytokine and other factors that may support hematopoiesis. Together, these results support previous observations made following xenotransplantation; for example, there was no evidence of frank immune rejection of undifferentiated UCMS cells. The results suggest that human UCMS will be tolerated in allogeneic transplantation.

Disclosure of potential conflicts of interest is found at the end of this article.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2008 by AlphaMed Press.